Target intelligence / Profile preview

Regulator of nonsense transcripts 1 (UPF1) (UPF1)

Target
UPF1
Molecular classification
RNA helicase (UniProt), ATPase (NCBI Gene), RNA-binding protein (Human Protein Atlas), Enzyme (UniProt)
01

Overview

Regulator of nonsense transcripts 1 (UPF1) is a highly conserved ATP-dependent RNA helicase that serves as the central engine of the nonsense-mediated mRNA decay (NMD) pathway (UniProt, PMC2991074). It functions as a molecular surveillance factor, identifying and targeting mRNAs with premature termination codons (PTCs) for rapid degradation to prevent the synthesis of truncated, potentially toxic proteins (NCBI Gene, PMC1782376). Beyond its primary role in NMD, UPF1 is involved in various other RNA decay pathways, DNA replication, and telomere maintenance, making it a critical regulator of cellular homeostasis (PMC2663315, Wikipedia). In disease contexts, UPF1 is often dysregulated; its downregulation is linked to several cancers where it acts as a tumor suppressor, while its modulation is being explored as a therapeutic strategy for genetic diseases caused by nonsense mutations (PMC9858311, Creative Biolabs). Pharmacological targeting of UPF1, primarily through small-molecule inhibitors that disrupt its interactions with other NMD factors like SMG5 or SMG7, aims to stabilize beneficial transcripts or enhance the efficacy of read-through therapies (AACR, PMC3518452). However, its essential role in development and genome stability presents significant challenges for therapeutic window and safety (PMC3603218, PMC2663315).

Other names
UPF1RENT1HUPF1SMG2NORF1ATP-dependent helicase RENT1Nonsense mRNA reducing factor 1Up-frameshift suppressor 1 homolog
02

Mechanism of action

Inhibition of nonsense-mediated mRNA decay (NMD) by disrupting UPF1 interactions with SMG proteins or inhibiting its ATPase/helicase activity (Santa Cruz Biotech, AACR, PMC3518452).

03

Biological functions

Nonsense-mediated mRNA decay (UniProt)mRNA surveillance (NCBI Gene)DNA replication (Wikipedia)Telomere maintenance (Wikipedia)Staufen1-mediated mRNA decay (PMC2663315)Histone mRNA decay (PMC2663315)
04

Disease associations

Cancer (PMC9858311)Neurodegenerative disease (PMC9858311)Genetic disorder (NCBI Gene)Infection (PMC9858311)
05

Safety considerations

Embryonic lethality (PMC3603218)Disruption of DNA replication and telomere maintenance (PMC2663315)Global stabilization of aberrant transcripts (Human Molecular Genetics)
06

Interacting drugs

Amlexanox (Santa Cruz Biotech)

4 more in the full profile.

07

Biomarkers

UPF1 expression levels (PMC9858311)PTC-containing mRNA levels (AACR)UPF1 phosphorylation status (Creative Biolabs)

Beyond the preview

Go deeper on Regulator of nonsense transcripts 1 (UPF1) (UPF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regulator of nonsense transcripts 1 (UPF1) (UPF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call